echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NAT MED: China's largest new crown antibody epidemic release

    NAT MED: China's largest new crown antibody epidemic release

    • Last Update: 2020-06-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Detection of asymptomatic or subclinical new human coronavirus SARS-CoV-2

    infection

    is critical to understanding the overall prevalence

    and

    potential of

    COVID-19





    Recently, in order to estimate the cumulative prevalence of SARS-CoV-2 infection in China, by measuring the levels of

    immuno
    globulinM M and G, Chinese researchers assessed host serum reactions in Wuhan, China, and various geographic regions of the country between March 9, 2020 and April 10, 2020



    in the queue, the seropositive rate of different subgroups in Wuhan was between 3.2% and 3.8%

    With the increase of distance from Wuhan, the seropositive in other cities gradually decreased

    Patients and health care providers who went to the hospital for maintenance hemodialysis also had a higher serum prevalence rate of 3.3% (51 out of 1,542, 5.5-4.3%, 95% Confidence Zone (CI) and 1.8% (81 out of 4,384, 1.5-2.3%, 95% CI)

    we need more research to determine whether these results can be extended to other populations and geographic locations, and to determine how rapidly serum prevalence increases as the COVID-19 pandemic progresses



    serological monitoring has the potential to provide a more faithful cumulative viral attack rate for the first season of this new type of SARS-CoV-2 infection







    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.